Coherus BioSciences Inc is a United States based biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Geographically, the group has a business presence in the United States and other countries.
| Website: | www.coherus.com |
| Email: | darrington@coherus.com |
| Main Phone: | +1 650 649-3530 |
| Address: | 333 Twin Dolphin Drive |
| Address 2: | Suite 600 |
| State: | CA |
| City / Town: | Redwood City |
| Country: | USA |
| Postal Code: | 94065 |
| Exchange: | NSD |
| CEO: | Dennis M. Lanfear |
| Employees: | 272 |
| NAICS: | Research and Development in Biotechnology (except Nanobiotechnology)(541714) |
The political pressure is not coming off healthcare, but have prices swung too far?
Coherus BioSciences (CHRS) is a late-stage clinical biologics platform company focused on the global biosimilar market. It is based in Redwood City, CA. Ten other companies are scheduled for the
Full IPO calendar & reports HERE. In order of largest IPO first. (1) Based in Denver, CO,Antero Midstream Partners LP (AM) scheduled a $750 million IPO on NYSE with a market
The Labor Department said Wednesday morning that its Consumer Price Index, a key measure of inflation, was flat in December, lead by a drop in gasoline prices, following a 0.3 percent increase in
Coherus BioSciences Inc is a United States based biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Geographically, the group has a business presence in the United States and other countries.
| Website: | www.coherus.com |
| Email: | darrington@coherus.com |
| Main Phone: | +1 650 649-3530 |
| Address: | 333 Twin Dolphin Drive |
| Address 2: | Suite 600 |
| State: | CA |
| City / Town: | Redwood City |
| Country: | USA |
| Postal Code: | 94065 |
| Exchange: | NSD |
| CEO: | Dennis M. Lanfear |
| Employees: | 272 |
| NAICS: | Research and Development in Biotechnology (except Nanobiotechnology)(541714) |
The political pressure is not coming off healthcare, but have prices swung too far?
Coherus BioSciences (CHRS) is a late-stage clinical biologics platform company focused on the global biosimilar market. It is based in Redwood City, CA. Ten other companies are scheduled for the
Full IPO calendar & reports HERE. In order of largest IPO first. (1) Based in Denver, CO,Antero Midstream Partners LP (AM) scheduled a $750 million IPO on NYSE with a market
The Labor Department said Wednesday morning that its Consumer Price Index, a key measure of inflation, was flat in December, lead by a drop in gasoline prices, following a 0.3 percent increase in
| Last Price 19.16 | Change $ -0.705 | Change % -3.55 | Tick N/A |
| Bid 18.00 | Bid Size 200.00 | Ask 21.25 | Ask Size 100.00 |
| Open 19.96 | High 19.96 | Low 18.98 | Prev Close 19.87 |
| Last Trade | Volume 833,379 | 52 Wk Hi 23.91 | 52 Wk Low 10.83 |
| Market Cap 1.3 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 70,129,340.00 | EPS (TTM) -0.17 | PE Ratio N/A | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 1 | 8 |
| Number of Buys | 0 | 5 |
| Number of Sells | 1 | 3 |
| Net Activity | -20984 | 3085 |
| Last 10 Buys | Shares |
|---|---|
| N/A | 0 |
| Last 10 Sell | Shares |
|---|---|
| Dennis M. Lanfear | 1,000 |
| Alan C. Herman | 1,000 |
| Alan C. Herman | 1,000 |
| Alan C. Herman | 1,000 |
| Alan C. Herman | 1,000 |
| Alan C. Herman | 1,000 |
| Alan C. Herman | 1,000 |
| Alan C. Herman | 1,000 |
| Alan C. Herman | 1,000 |
| Alan C. Herman | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 45 | 45 | 45 | 45 |
| Low Target Price Estimate | 22 | 22 | 22 | 22 |
| Mean Target Price Estimate | 28.4 | 28.4 | 28.4 | 28.4 |
| Standard Deviation | 9.61 | 9.61 | 9.61 | 9.61 |
| Date of Most Recent Estimate | 05/17/18 | 05/17/18 | 05/14/18 | 05/17/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| S-8 | Securities offered to employees under employee benefit plans | 9 | 2018-06-14 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-05-29 |
| 8-K | Report of unscheduled material events or corporate changes. | 53 | 2018-05-25 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 64 | 2018-05-23 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 64 | 2018-05-21 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-16 |
| 8-K | Report of unscheduled material events or corporate changes. | 5 | 2018-05-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 6 | 2018-05-14 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-11 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait